术后小细胞肺癌患者预防性脑照射研究进展

doi:10.3760/cma.j.issn.1004-4221.2018.11.018

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

小细胞肺癌(SCLC)发病数较少,约占所有支气管肺癌的13%~20%,恶性程度较高,短时间内易复发转移。确诊时局限期小细胞肺癌约占SCLC的30%,符合手术患者仅占5%。放化疗后完全缓解者仍有一半以上患者发生脑转移。术后Ⅰ、Ⅱ、Ⅲ期SCLC患者脑转移发生率为6%~14%、13%~38%、11%~36%。预防性脑照射(PCI)可提高放化疗后完全缓解者总生存率,并降低脑转移发生率,是局限期SCLC综合治疗的重要组成部分。但是,PCI的临床应用仍存一些争议,手术完全切除的SCLC患者行PCI的疗效不一。本文对此问题进行文献综述,并介绍该领域的研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈梦圆
	胡晓
	王谨
	陈明

关键词 ：肺肿瘤/术后预防性脑照射, 预后, 研究进展

Abstract：

The incidence of small cell lung cancer (SCLC) is relatively low, which approximately accounts for 13%-20% of all types of lung cancers. SCLC is characterized by high-degree malignancy and high metastasis and recurrence rates within a short period of time. Upon the confirmed diagnosis, limited-stage SCLC approximately accounted for 30% of SCLC and merely 5% of these patients were eligible for surgery. Over half of the patients who obtained complete remission after chemoradiotherapy presented with brain metastases. The postoperative incidence of brain metastases in patients with stage Ⅰ, Ⅱ and Ⅲ SCLC was 6%-14%,13%-38% and 11%-36%, respectively. Prophylactic cranial irradiation (PCI) can enhance the overall survival rate of patients with complete remission after chemoradiotherapy and reduce the incidence of brain metastasis, which is a pivotal part of comprehensive treatment of limited-stage SCLC. However, the application of PCI remains controversial in clinical practice and the clinical efficacy for patients with surgically resected SCLC significantly varies. In this article, literature review was conducted and the research progress in this field was summarized.

Key words： Lung neoplasm/postoperative prophylactic cranial irradiation Prognosis Reasearch progress

收稿日期: 2018-05-10

基金资助:

国家自然科学基金(81402540、81401911、81672972);国家卫生计生委科学研究基金—浙江省医药卫生重大科技计划(省部共建计划)项目(WKJ-ZJ-1701)

通讯作者: 陈明,Email:chenming@zjcc.org.cn

引用本文:

陈梦圆,胡晓,王谨等. 术后小细胞肺癌患者预防性脑照射研究进展[J]. 中华放射肿瘤学杂志, 2018, 27(11): 1026-1029.

Chen Mengyuan,Hu Xiao,Wang Jin et al. Research progress on prophylactic cranial irradiation in patients with surgically resected small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(11): 1026-1029.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.11.018 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I11/1026

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].Clin Oncol,2006,24(28):4539-4544.DOI:10.1200/JCO.2005.04.485.
[2] Arriagada R,Le Chevalier T,Borie F,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J].J Natl Cancer Inst,1995,87(3):183-190. DOI:10.1093/jnci/87.3.183.
[3] Aupérin A,Arriagada R,Pignon JP,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J].JNEJ Med,1999,341(7):476-484.DOI:10.1056/NEJM199908123410703.
[4] Bloom BC, Augustyn A, Sepesi B,et al. Prophylactic cranial irradiation following surgical resection of early-stage small-cell lung cancer:a review of the literature[J].Front Oncol,2017,7:228.DOI:10.3389/fonc.2017.00228.
[5] Fox W,Scadding JG.Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up[J].Lancet,1973,2(7820):63-65.DOI:10.1016/S0140-6736(73)93260-1.
[6] Pignon JP,Arriagada R,Ihde DC,et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer[J].N Engl J Med,1992,327(23):1618-1624.DOI:10.1056/NEJM199212033272302.
[7] Warde P,Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung?A meta-analysis[J].J Clin Oncol,1992,10(6):890-895.DOI:10.1016/0360-3016(90)90695-G.
[8] Lim E,Belcher E,Yap YK,et al. The role of surgery in the treatment of limited disease small cell lung cancer:time to reevaluate[J].J Thorac Oncol,2008,3(11):1267-1271.DOI:10.1097/JTO.0b013e318189a860.
[9] Rostad H,Naalsund A,Jacobsen R,et al. Small cell lung cancer in Norway. Should more patients have been offered surgical therapy?[J].Eur J Cardiothorac Surg,2004,26(4):782-786. DOI:10.1016/j.ejcts.2004.06.011.
[10] Inoue M,Miyoshi S,Yasumitsu T,et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University,Osaka,Japan[J].Ann Thorac Surg,2000,70(5):1615-1619.DOI:10.1016/S0003-4975(00)01401-6
[11] Weksler B,Nason KS,Shende M,et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung[J].Ann Thorac Surg,2012,94(3):889-893.DOI:10.1016/j.athoracsur.2012.01.015.
[12] Yu JB,Decker RH,Detterbeck FC,et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage Ⅰ small cell lung cancer[J].J Thorac Oncol,2010,5(2):215-219.DOI:10.1097/JTO.0b013e3181cd3208.
[13] Schreiber D,Rineer J,Weedon J,et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer:should its role be re-evaluated?[J].Cancer,2010,116(5):1350-1357.DOI:10.1002/cncr.24853.
[14] National comprehensive cancer network:NCCN clinical practice guidelines in oncology:small cell lung cancer (version 1.2016)[M].Washington:National comprehensive cancer network,2016.
[15] Halthore A,Goenka A,Sharma R,et al. Prophylactic cranial irradiation for resectable small cell lung cancer[J].Clin Lung Cancer,2017.DOI:10.1016/ j.cllc.2017.08.004.
[16] Gong L,Wang QI,Zhao L,et al. Factors affecting the risk of brain metastasisin small cell lung cancer with surgery:is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease?[J].Int J Radiation Oncol Biol Phys,2013,85(1):196-200.DOI:10.1016/j.ijrobp.2012.03.038.
[17] Nakamura H,Kato Y,Kato H,et al. Outcome of surgery for small-cell lung cancer-response to induction chemotherapy predicts survival[J].Thorac Cardiovasc,2004,52(4):206-210.DOI:10.1055/s-2004-821075
[18] Tsuchiya R,Suzuki K,Ichinose Yet,et al. Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ–ⅢA small-cell lung cancer:the Japan clinical oncology lung cancer study group trial (JCOG9101)[J].J Thorac Cardiovasc Surg,2005,129(5):977-983. DOI:10.1016/j.jtcvs.2004.05.030
[19] Hui Z,Hongbo G,Fang S,et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer,but not for stage Ⅰ disease[J].Lung Cancer,2014,86(3):334-338. DOI:10.1016/j.lungcan.2014.09.019.
[20] Xu J,Yang H,Fu X,et al. Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. J Thorac Oncol,2017,12(2):347-357.DOI:10.1016/j.jtho.2016.09.133.
[21] Bischof M,Debus J,Herarth K,et al. Surgery and chemotherapy for small-cell lung cancer in stages Ⅰ-Ⅱ with or without radiotherapy[J].Strahlenther Onkol,2007,183(12):679-684.DOI:10.1007/s00066-007-1740-z.
[22] Chi-Fu JY,Derek Y,Paul J,et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer[J].J Clin Oncol,2016,34(10):1057-1064.DOI:10.1200/JCO.2015.63.8171.
[23] Verma V,Nd SC,Allen PK,et al. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation:a multicenter analysis[J].Clin Lung Cancer,2017,pii:S1525-7304(17)30086-4.DOI:10.1016/j.cllc.2017.03.009.
[24] Gregor A,Cull A,Stephens RJ,et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer:results of a multicenter randomised trial[J].Eur J Cancer,1997,33(11):1752-1758.DOI:10.1016/S0959-8049(97)00135-4.
[25] Grosshans DR,Meyers CA,Allen PK,et al. Neurocognitive function in patients with small cell lung cancer:effect of prophylactic cranial irradiation[J].Cancer,2008,112(3):589-595.DOI:10.1002/cncr.23222.
[26] Le Pechoux C,Laplanche A,Faivre-Finn C,et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase Ⅲ trial (PCI99-01,EORTC 22003-08004,RTOG 0212 and IFCT 99-01)[J].Ann Oncol,2011,22(5):1154-1163.DOI:10.1093/annonc/mdq576.
[27] Craig J,Jackson D,Moody D,et al. Prospective evaluation of changes in computerized cranial tomography (CCT) in patients with small-cell carcinoma (SCLC) treated with chemotherapy and cranial irradiation[J].J Clin Oncol,1984,2(10):1151-1156.DOI:10.1200/JCO.1984.2.10.1151.
[28] Fonseca R,O′Neill BP,Foote RL,et al. Cerebral toxicity in patients treated for small-cell carcinoma of the lung[J].Mayo Clin Proc,1999,74(5):461-465. DOI:10.4065/74.5.461.
[29] Shaw MG,Ball DL.Treatment of brain metastases in lung cancer:strategies to avoid/reduce late complications of whole brain radiation therapy[J].Curr Treat Options Oncol,2013,14(4):553-567.DOI:10.1007/s11864-013-0258-0.
[30] Schloesser D, Moore E, Robbins ME. Molecular pathways:radiation-induced cognitive impairment[J].Clin Cancer Res,2013,19(9):2294-2300.DOI:10.1158/1078-0432.CCR-11-2903.
[31] Gondi V,Tome WA,Marsh J,et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy:safety profile for RTOG 0933[J].Radiother Oncol,2010,95(3):327-331.DOI:10.1016/j.radonc.2010.02.030.
[32] Ghia A,Tome WA,Thomas S,et al. Distribution of brain metastasis in relation to the hippocampus:implications for neurocognitive functional preservation[J].Int J Radiat Oncol Biol Phys,2007,68(4):971-977.DOI:10.1016/j.ijrobp.2007.02.016.
[33] Kundapur V,Ellchuk T,Ahmed S,et al. Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation:a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation[J].Int J Radiat Oncol Biol Phys,2015,91(4):781-786.DOI:10.1016/j.ijrobp. 2014.12.026.
[34] Gondi V,Pugh SL,Tome WA,et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase Ⅱ multi-institutional trial[J].J Clin Oncol,2014,32(34):3810-3816.DOI:0.1200/JCO.2014.57.2909.
[35] Korkmaz Kirakli E,Oztekin O.Is hippocampal avoidance during whole-brain radiotherapy risky for patients with small-cell lung cancer? Hippocampal metastasis rate and associated risk factors[J].Technol Cancer Res Treat,2017 16(6):1202-1208.DOI:10.1177/1533034617742301.